Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice

Matrix Biology

Volumn 23, Issue 7, 2004, Pages 421-432

  Sitara, Despina ^a   Razzaque, Mohammed S ^a   Hesse, Martina ^b   Yoganathan, Subbiah ^a   Taguchi, Takashi ^c   Erben, Reinhold G ^b   Jüppner, Harald ^d   Lanske, Beate ^a  

^a FORSYTH INSTITUTE   (United States)

^b UNIVERSITY OF MUNICH   (Germany)

^c NAGASAKI UNIVERSITY   (Japan)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Bone; Fgf 23 null; Hyp; Mineralization; Phosphate

Indexed keywords

FIBROBLAST GROWTH FACTOR; PROTEINASE;

ANIMAL MODEL; ARTICLE; BETA GALATOSIDASE GENE; BONE DENSITY; BONE DEVELOPMENT; BONE MINERAL; BONE MINERALIZATION; CHROMOSOME; CONTROLLED STUDY; CORRELATION ANALYSIS; EXPERIMENTAL MODEL; FIBROBLAST GROWTH FACTOR 23 GENE; GENE; HEART; HOMEOSTASIS; HOMOZYGOSITY; HYPERPHOSPHATEMIA; HYPOPHOSPHATEMIA; KIDNEY; MOLECULAR BIOLOGY; MORPHOMETRICS; MOUSE; NONHUMAN; NULL ALLELE; PATHOPHYSIOLOGY; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; SOFT TISSUE; X CHROMOSOME;

ALLELES; ANIMALS; ANTHRAQUINONES; BLOTTING, SOUTHERN; BONE AND BONES; CELL PROLIFERATION; CHROMOSOMES, HUMAN, X; FEMALE; FIBROBLAST GROWTH FACTORS; HOMOZYGOTE; HUMANS; HYPOPHOSPHATEMIA; IN SITU HYBRIDIZATION; LAC OPERON; LINKAGE (GENETICS); MALE; MICE; MICE, TRANSGENIC; MODELS, GENETIC; MUTATION; OSTEOMALACIA; PHEX PHOSPHATE REGULATING NEUTRAL ENDOPEPTIDASE; PHOSPHATES; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); PROTEINS; RNA, MESSENGER; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; X-RAYS;

ANIMALIA; MURINAE;

EID: 9644303231     PISSN: 0945053X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.matbio.2004.09.007     Document Type: Article

References (60)

1. ADHR_Consortium Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. The ADHR Consortium Nat. Genet. 26 2000 345 348
2. A.C. Alfrey, G.R. LeGendre, and W.D. Kaehny The dialysis encephalopathy syndrome. Possible aluminum intoxication N. Engl. J. Med. 294 1976 184 188
3. Y. Aono, T. Shimada, Y. Yamaziki, R. Hino, Y. Takeuchi, T. Fujita, S. Fukumoto, N. Nagano, M. Wada, and T. Yamashita The neutralization of FGF-23 ameliorates hypophosphatemia and rickets in Hyp mice J. Bone Miner. Res. 18 Suppl. 2 2003 1056
4. L. Argiro, M. Desbarats, F.H. Glorieux, and B. Ecarot Mepe, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteomalacia, is expressed in bone Genomics 74 2001 342 351
5. X. Bai, D. Miao, D. Panda, S. Grady, M.D. McKee, D. Goltzman, and A.C. Karaplis Partial rescue of the Hyp phenotype by osteoblast-targeted PHEX (phosphate-regulating gene with homologies to endopeptidases on the X chromosome) expression Mol. Endocrinol. 16 2002 2913 2925
6. X.Y. Bai, D. Miao, D. Goltzman, and A.C. Karaplis The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency J. Biol. Chem. 278 2003 9843 9849
7. X. Bai, D. Miao, J. Li, D. Goltzman, and A.C. Karaplis Transgenic mice overexpressing human fibroblast growth factor 23(R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders Endocrinology 145 2004 5269 5279
8. T. Berndt, T.A. Craig, A.E. Bowe, J. Vassiliadis, D. Reczek, R. Finnegan, S.M. Jan De Beur, S.C. Schiavi, and R. Kumar Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent J. Clin. Invest. 112 2003 785 794
9. G.A. Block, and F.K. Port Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management Am. J. Kidney Dis. 35 2000 1226 1237
10. G.A. Block, T.E. Hulbert-Shearon, N.W. Levin, and F.K. Port Association of serum phosphorus and calcium +ANc phosphate product with mortality risk in chronic hemodialysis patients: a national study Am. J. Kidney Dis. 31 1998 607 617
11. A.E. Bowe, R. Finnegan, S.M. Jan de Beur, J. Cho, M.A. Levine, R. Kumar, and S.C. Schiavi FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate Biochem. Biophys. Res. Commun. 284 2001 977 981
12. A. Bradley Production and analysis of chimeric mice E.J. Robertson Teratocarcinomas and Embryonic Stem Cells: A Practical Approach 1987 IRL Press Washington, DC 113 152
13. M. Campos, C. Couture, I.Y. Hirata, M.A. Juliano, T.P. Loisel, P. Crine, L. Juliano, G. Boileau, and A.K. Carmona Human recombinant PHEX has a strict S1+IDI specificity for acidic residues and cleaves peptides derived from FGF-23 and MEPE Biochem. J. 373 2003 271 279
14. T.O. Carpenter Oncogenic osteomalacia+IBQ-a complex dance of factors N. Engl. J. Med. 348 2003 1705 1708
15. G.M. Chertow, S.K. Burke, J.M. Lazarus, K.H. Stenzel, D. Wombolt, D. Goldberg, J.V. Bonventre, and E. Slatopolsky Poly(allylamine hydrochloride) (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure Am. J. Kidney Dis. 29 1997 66 71
16. A.J. Collins, S. Li, J.Z. Ma, and C. Herzog Cardiovascular disease in end-stage renal disease patients Am. J. Kidney Dis. 38 2001 S26 S29
17. S.M. De Beur, R.B. Finnegan, J. Vassiliadis, B. Cook, D. Barberio, S. Estes, P. Manavalan, J. Petroziello, S.L. Madden, and J.Y. Cho Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism J. Bone Miner. Res. 17 2002 1102 1110
18. M. Drezner Phosphorus homeostasis and related disorders J. Bilezikian L. Raisz G. Rodan Principles in Bone Biology 2002 Academic Press New York 321 338
19. L. Du, M. Desbarats, J. Viel, F.H. Glorieux, C. Cawthorn, and B. Ecarot cDNA cloning of the murine Pex gene implicated in X-linked hypophosphatemia and evidence for expression in bone Genomics 36 1996 22 28
20. C.R. Dunstan, H. Zhou, and M.J. Seibel Fibroblast growth factor 23: a phosphatonin regulating phosphate homeostasis? Endocrinology 145 2004 3084 3086
21. M.J. Econs, P.T. McEnery, F. Lennon, and M.C. Speer Autosomal dominant hypophosphatemic rickets is linked to chromosome 12p13 J. Clin. Invest. 100 1997 2653 2657
22. S.K. Ganesh, A.G. Stack, N.W. Levin, T. Hulbert-Shearon, and F.K. Port Association of elevated serum PO(4), Ca +ANc PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients J. Am. Soc. Nephrol. 12 2001 2131 2138
23. I.A. Holm, X. Huang, and L.M. Kunkel Mutational analysis of the PEX gene in patients with X-linked hypophosphatemic rickets Am. J. Hum. Genet. 60 1997 790 797
24. HYP_Consortium A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets Nat. Genet. 11 1995 130 136
25. Y. Imanishi, M. Inaba, K. Nakatsuka, K. Nagasue, S. Okuno, A. Yoshihara, M. Miura, A. Miyauchi, K. Kobayashi, and T. Miki FGF-23 in patients with end-stage renal disease on hemodialysis Kidney Int. 65 2004 1943 1946
26. K.B. Jonsson, R. Zahradnik, T. Larsson, K.E. White, T. Sugimoto, Y. Imanishi, T. Yamamoto, G. Hampson, H. Koshiyama, and O. Ljunggren Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia N. Engl. J. Med. 348 2003 1656 1663
27. A.C. Karaplis, A. Luz, J. Glowacki, R.T. Bronson, V.L. Tybulewicz, H.M. Kronenberg, and R.C. Mulligan Lethal skeletal dysplasia from targeted disruption of the parathyroid hormone-related peptide gene Genes Dev. 8 1994 277 289
28. H.M. Kronenberg Developmental regulation of the growth plate Nature 423 2003 332 336
29. B. Lanske, P. Divieti, C. Kovacs, A. Pirro, W. Landis, S. Krane, F. Bringhurst, and H. Kronenberg The parathyroid hormone/parathyroid hormone-related peptide receptor mediates actions of both ligands in murine bone Endocrinology 139 1998 5194 5204
30. T. Larsson, U. Nisbeth, O. Ljunggren, H. Juppner, K.B. Jonsson, M. Riminucci, M.T. Collins, N.S. Fedarko, N. Cherman, and A. Corsi Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers Kidney Int. 64 2003 2272 2279
31. T. Larsson, R. Marsell, E. Schipani, C. Ohlsson, O. Ljunggren, H.S. Tenenhouse, H. Juppner, and K.B. Jonsson Transgenic mice expressing fibroblast growth factor 23 under the control of the {alpha}1(I) collagen promoter exhibit growth retardation, osteomalacia and disturbed phosphate homeostasis Endocrinology 145 2004 3087 3094
32. S. Liu, R. Guo, L.G. Simpson, Z.S. Xiao, C.E. Burnham, and L.D. Quarles Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX J. Biol. Chem. 278 2003 37419 37426
33. B. Lorenz-Depiereux, V.E. Guido, K.R. Johnson, Q.Y. Zheng, L.H. Gagnon, J.D. Bauschatz, M.T. Davisson, L.L. Washburn, L.R. Donahue, T.M. Strom, and E.M. Eicher New intragenic deletions in the Phex gene clarify X-linked hypophosphatemia-related abnormalities in mice Mamm. Genome 15 2004 151 161
34. M.J. McLeod Differential staining of cartilage and bone in whole fetuses by alcian blue and alizarin red S Teratology 22 1980 299 301
35. F. Meric, P. Yap, and M.J. Bia Etiology of hypercalcemia in hemodialysis patients on calcium carbonate therapy Am. J. Kidney Dis. 16 1990 459 464
36. D. Miao, X. Bai, D. Panda, M. McKee, A. Karaplis, and D. Goltzman Osteomalacia in hyp mice is associated with abnormal phex expression and with altered bone matrix protein expression and deposition Endocrinology 142 2001 926 939
37. A.E. Nelson, R.C. Bligh, M. Mirams, A. Gill, A. Au, A. Clarkson, H. Juppner, S. Ruff, P. Stalley, and R.A. Scolyer Clinical case seminar: fibroblast growth factor 23: a new clinical marker for oncogenic osteomalacia J. Clin. Endocrinol. Metab. 88 2003 4088 4094
38. S.M. Ott, N.A. Maloney, J.W. Coburn, A.C. Alfrey, and D.J. Sherrard The prevalence of bone aluminum deposition in renal osteodystrophy and its relation to the response to calcitriol therapy N. Engl. J. Med. 307 1982 709 713
39. L.D. Quarles FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization Am. J. Physiol: Endocrinol. Metab. 285 2003 E1 E9
40. M. Riminucci, M.T. Collins, N.S. Fedarko, N. Cherman, A. Corsi, K.E. White, S. Waguespack, A. Gupta, T. Hannon, and M.J. Econs FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting J. Clin. Invest. 112 2003 683 692
41. P.S. Rowe, Y. Kumagai, G. Gutierrez, I.R. Garrett, R. Blacher, D. Rosen, J. Cundy, S. Navvab, D. Chen, and M.K. Drezner MEPE has the properties of an osteoblastic phosphatonin and minhibin Bone 34 2004 303 319
42. H. Saito, K. Kusano, M. Kinosaki, H. Ito, M. Hirata, H. Segawa, K. Miyamoto, and N. Fukushima Human fibroblast growth factor-23 mutants suppress Na+ - dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production J. Biol. Chem. 278 2003 2206 2211
43. R. Schenk, A. Olah, and W. Herrmann Preparation of calcified tissues for light microscopy G. Dickson Methods of Calcified Tissue Preparation 1984 Elsevier Amsterdam 1 56
44. S.C. Schiavi, and R. Kumar The phosphatonin pathway: new insights in phosphate homeostasis Kidney Int. 65 2004 1 14
45. J. Seufert, K. Ebert, J. Muller, J. Eulert, C. Hendrich, E. Werner, N. Schuuze, G. Schulz, W. Kenn, and H. Richtmann Octreotide therapy for tumor-induced osteomalacia N. Engl. J. Med. 345 2001 1883 1888
46. T. Shimada, S. Mizutani, T. Muto, T. Yoneya, R. Hino, S. Takeda, Y. Takeuchi, T. Fujita, S. Fukumoto, and T. Yamashita Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia Proc. Natl. Acad. Sci. U. S. A. 98 2001 6500 6505
47. T. Shimada, T. Muto, I. Urakawa, T. Yoneya, Y. Yamazaki, K. Okawa, Y. Takeuchi, T. Fujita, S. Fukumoto, and T. Yamashita Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo Endocrinology 143 2002 3179 3182
48. T. Shimada, M. Kakitani, Y. Yamazaki, H. Hasegawa, Y. Takeuchi, T. Fujita, S. Fukumoto, K. Tomizuka, and T. Yamashita Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism J. Clin. Invest. 113 2004 561 568
49. T. Shimada, I. Urakawa, Y. Yamazaki, H. Hasegawa, R. Hino, T. Yoneya, Y. Takeuchi, T. Fujita, S. Fukumoto, and T. Yamashita FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type Iia Biochem. Biophys. Res. Commun. 314 2004 409 414
50. E. Slatopolsky, C. Weerts, S. Lopez-Hilker, K. Norwood, M. Zink, D. Windus, and J. Delmez Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis N. Engl. J. Med. 315 1986 157 161
51. E.A. Slatopolsky, S.K. Burke, and M.A. Dillon RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group Kidney Int. 55 1999 299 307
52. G.J. Strewler FGF23, hypophosphatemia, and rickets: has phosphatonin been found? Proc. Natl. Acad. Sci. U. S. A. 98 2001 5945 5946
53. T. Strom, F. Francis, B. Lorenz, A. B+APY-ddrich, M. Econs, H. Lehrach, and T. Meitinger Pex gene deletions in Gy and Hyp mice provide mouse models for X-linked hypophosphatemia Hum. Mol. Genet. 6 1997 165 171
54. H.S. Tenenhouse X-linked hypophosphataemia: a homologous disorder in humans and mice Nephrol. Dial. Transplant. 14 1999 333 341
55. T.J. Weber, S. Liu, O.S. Indridason, and L.D. Quarles Serum FGF23 levels in normal and disordered phosphorus homeostasis J. Bone Miner. Res. 18 2003 1227 1234
56. K.E. White, K.B. Jonsson, G. Carn, G. Hampson, T.D. Spector, M. Mannstadt, B. Lorenz-Depiereux, A. Miyauchi, I.M. Yang, and O. Ljunggren The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting J. Clin. Endocrinol. Metab. 86 2001 497 500
57. K.E. White, S.G. Waguespack, and M.J. Econs Case 29-2001: oncogenic hypophosphatemic osteomalacia N. Engl. J. Med. 346 2002 381 382
58. Z.S. Xiao, M. Crenshaw, R. Guo, T. Nesbitt, M.K. Drezner, and L.D. Quarles Intrinsic mineralization defect in hyp mouse osteoblasts Am. J. Physiol: Endocrinol. Metab. 38 1998 E 700 E 708
59. T. Yamashita, M. Yoshioka, and N. Itoh Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain Biochem. Biophys. Res. Commun. 277 2000 494 498
60. Y. Yamazaki, R. Okazaki, M. Shibata, Y. Hasegawa, K. Satoh, T. Tajima, Y. Takeuchi, T. Fujita, K. Nakahara, T. Yamashita, and S. Fukumoto Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia J. Clin. Endocrinol. Metab. 87 2002 4957 4960